Why the study?
S-ICDs offer an alternative to transvenous systems in Brugada syndrome, but electrocardiographic eligibility needed to be evaluated after exercise stress testing.
Does exercise stress testing alter electrocardiographic eligibility for subcutaneous implantable cardioverter-defibrillator (S-ICD) in patients with Brugada syndrome?
Does exercise stress testing alter electrocardiographic eligibility for subcutaneous implantable cardioverter-defibrillator (S-ICD) in patients with Brugada syndrome?
Screening after exercise stress testing is crucial in Brugada syndrome patients considered for S-ICD, as a significant proportion lose eligibility post-exercise, which may help avoid inappropriate therapies.
Answers are grounded in this paper and cite their sources.
May warrant post-exercise screening before S-ICD in Brugada syndrome; leaves open prospective validation before practice change.
Brugada syndrome (BrS) is a channelopathy associated with ventricular arrhythmias and sudden cardiac death. In patients at high risk of sudden death, an implantable cardioverter-defibrillator is indicated. Subcutaneous implantable cardioverter-defibrillators (S-ICDs) are an alternative to transvenous systems, with reduced risk of infection and complications associated with system extraction or explantation. To test electrocardiographic eligibility for S-ICD placement after exercise stress testing (EST) in patients with BrS. The sample included 35 consecutive patients with BrS. Electrocardiographic eligibility was assessed using the Boston Scientific model 2889 EMBLEM™ S-ICD automated screening tool, in four phases: decubitus and orthostatism, and before and after EST. Those who had at least one acceptable vector in the four measurements were considered eligible. In this study, 71.4% of patients were male and mean age was 53.86±12 years. In screening prior to EST, 14.3% of patients (n=5) were not eligible for an S-ICD. There was a statistically significant association between ineligibility and presence of complete right bundle branch block and history of syncope. After EST, 16.7% of initially eligible patients no longer had eligible vectors (n=5). In this study, 16.7% of patients previously eligible for an S-ICD were no longer eligible after EST. This result demonstrates the importance of screening after EST in all patients with BrS and with indication for an S-ICD, and may influence decisions concerning which ICD to implant or whether to institute pharmacological measures that avoid inappropriate therapies. A síndrome de Brugada (SBr) é uma canalopatia associada ao desenvolvimento de arritmias ventriculares e morte súbita cardíaca. Pacientes com alto risco devem ser orientados para a colocação um cardioversor-desfibrilhador. O cardioversor-desfibrilhador implantável subcutâneo (CDI-S) é uma alternativa ao sistema transvenoso, com menor risco de infeção e complicações associadas à extração/explante do sistema. Testar a elegibilidade eletrocardiográfica para colocação de CDI-S após prova de esforço (PE) em pacientes com SBr. A amostra incluiu 35 pacientes, consecutivos, com SBr. A elegibilidade eletrocardiográfica foi avaliada pela ferramenta de rastreio automática, Boston-Emblem S-ICD (Modelo 2889)®, em quatro fases: decúbito e ortostatismo, antes e depois da PE – foram considerados elegíveis indivíduos que tinham pelo menos um vetor aceitável nas quatro fases. Neste estudo, 71,4% dos pacientes eram do sexo masculino, com idade média de 53,86±12 anos. No rastreio anterior à PE, 14,3% dos pacientes (n=5) não eram elegíveis para o implante de CDI-S. Demonstrou-se uma associação significativa entre não elegibilidade e a presença de bloqueio de ramo direito e história de síncope. Após a PE, 16,7% dos pacientes inicialmente elegíveis deixaram de ter vetores aceitáveis para a implantação de CDI-S (n=5). Neste estudo, 16,7% dos pacientes previamente elegíveis para CDI-S deixaram de o ser após a PE. Estes resultados demonstram a relevância do rastreio após PE em todos os pacientes com SBr e com indicação para CDI-S, influenciando a decisão do sistema a implantar ou medidas farmacológicas que evitem casos de terapias inadequadas.
No takes yet. Share an insight, caveat, or question.
Hafe et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: